Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis

Complete Regression of Psoriatic Arthritis After Belatacept Conversion in a Highly HLA-Sensitized Kidney Transplant Patient

“…Previous studies that used abatacept in PsA showed a successful clinical response in most cases, in addition to a significant regression of synovial cell infiltration and downregulation of T helper 1 cells and inflammatory chemokines, emphasizing a mechanistic role of costimulation blockade in this T cell-mediated disease (7,17). Importantly, in a recent double-blind RCT using abatacept in PsA, Mease et al (8) reported significantly higher clinical and radiological responses compared with placebo with good safety profile, results that are currently being further validated in an ongoing multicenter phase 3 RCT (ClinicalTrials.gov identifier: NCT01860976).…”

“…Because activated T cells play a central role in PsA, costimulation blockade at the B7 family (CD80/CD86)-CD28 level using abatacept, a fully human fusion protein, has been proposed and showed promising results in PsO and PsA (6,7). In PsA, abatacept was shown to be effective compared with placebo in a phase 2 randomized controlled trial (RCT) showing significant clinical and radiological improvement (8).…”

Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system

“…In 2007, administration of CTLA4-Ig (abatacept) blocking the interaction of CD28 with its ligands B7-1 (CD80) and B7-2 (CD86) in patients with RA has been approved by the European Medical Drug Agency. Success has been noted in psoriatic arthritis [67]. Its use in IBD is ongoing, and Phase II and III studies are planned.…”

The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis

“…These observations of abatacept in PsO and other inflammatory arthritides spurred the development of trials in PsA. Initial case reports in PsA of two patients who previously failed TNF inhibitors described significant improvement in clinical signs and symptoms of PsA after regular treatment with abatacept [72, 73]. Formal investigation by Mease et al [70, 74] confirmed a significant ACR20 response in patients randomized to 10 mg/kg abatacept compared to placebo (48% vs. 19%, P  = 0.006), but no significant difference in those treated with 3 mg/kg abatacept.…”